[go: up one dir, main page]

MX2021002380A - Conjugados de isoquinolina-esteroide y usos de los mismos. - Google Patents

Conjugados de isoquinolina-esteroide y usos de los mismos.

Info

Publication number
MX2021002380A
MX2021002380A MX2021002380A MX2021002380A MX2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A MX 2021002380 A MX2021002380 A MX 2021002380A
Authority
MX
Mexico
Prior art keywords
methods
compounds
isoquinoline
subject
kinase activity
Prior art date
Application number
MX2021002380A
Other languages
English (en)
Inventor
Mitchell A Delong
Eric Carlson
Jill M Sturdivant
Casey Kopczynski
Cynthia L Lichorowic
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of MX2021002380A publication Critical patent/MX2021002380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporcionan en la presente compuestos y composiciones farmacéuticas útiles para modular la actividad de cinasa y enfermedades relacionadas. También se proporcionan métodos para tratar una enfermedad o trastorno ocular en un sujeto. También se proporcionan en la presente métodos para reducir la presión intraocular en un sujeto. También se proporcionan en la presente métodos para modular la actividad de cinasa en una célula. También se proporcionan en la presente métodos para hacer los compuestos provistos en la presente y compuestos útiles para la preparación de los compuestos provistos en la presente.
MX2021002380A 2018-08-31 2019-08-30 Conjugados de isoquinolina-esteroide y usos de los mismos. MX2021002380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725941P 2018-08-31 2018-08-31
PCT/US2019/049195 WO2020047496A1 (en) 2018-08-31 2019-08-30 Isoquinoline-steroid conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2021002380A true MX2021002380A (es) 2021-07-15

Family

ID=69639319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002380A MX2021002380A (es) 2018-08-31 2019-08-30 Conjugados de isoquinolina-esteroide y usos de los mismos.

Country Status (10)

Country Link
US (2) US11059789B2 (es)
EP (1) EP3843736A4 (es)
JP (1) JP7437384B2 (es)
KR (1) KR20210053301A (es)
CN (1) CN112638386A (es)
AU (2) AU2019328590B2 (es)
BR (1) BR112021003613A2 (es)
MX (1) MX2021002380A (es)
SG (1) SG11202101517PA (es)
WO (1) WO2020047496A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7437384B2 (ja) 2018-08-31 2024-02-22 アエリエ ファーマシューティカルズ インコーポレイテッド イソキノリンステロイド抱合体およびその使用
WO2021024039A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependance disorders
US20230149387A1 (en) * 2020-04-08 2023-05-18 Aerie Pharmaceuticals, Inc. Treatments
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
US20240343755A1 (en) * 2021-04-29 2024-10-17 Alcon Inc. Stable isoquinoline-corticosteroid conjugates and uses thereof
US20250057962A1 (en) * 2021-11-03 2025-02-20 Ripple Therapeutics Corporation Processable compositions and use for the same
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3193459A (en) 1955-07-01 1965-07-06 Upjohn Co Steroid hemisuccinate compositions and method for extemporaneous administration
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
MX2009008334A (es) * 2007-02-05 2009-08-12 Nicox Sa Esteroides que liberan oxido nitrico.
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
RU2015135145A (ru) 2013-03-08 2017-04-13 Аллерган, Инк. Циклоспорин а-стероидные конъюгаты
EP2964266A1 (en) 2013-03-08 2016-01-13 Allergan, Inc. Antibiotic conjugates directly linked with steroid drugs
EP2976080B1 (en) * 2013-03-15 2019-12-25 Aerie Pharmaceuticals, Inc. Conjugates of isoquinoline compounds and prostaglandins
WO2018034702A1 (en) * 2016-08-19 2018-02-22 Aerie Pharmaceuticals, Inc. Beta-amino-isoquinolinyl amide compounds
JP7437384B2 (ja) 2018-08-31 2024-02-22 アエリエ ファーマシューティカルズ インコーポレイテッド イソキノリンステロイド抱合体およびその使用

Also Published As

Publication number Publication date
AU2019328590A1 (en) 2021-03-11
JP7437384B2 (ja) 2024-02-22
WO2020047496A1 (en) 2020-03-05
US11691950B2 (en) 2023-07-04
BR112021003613A2 (pt) 2021-05-18
AU2023204624A1 (en) 2023-08-03
AU2019328590B2 (en) 2023-04-13
CN112638386A (zh) 2021-04-09
US20210300874A1 (en) 2021-09-30
KR20210053301A (ko) 2021-05-11
SG11202101517PA (en) 2021-03-30
EP3843736A1 (en) 2021-07-07
EP3843736A4 (en) 2022-06-15
US20200071275A1 (en) 2020-03-05
JP2021535147A (ja) 2021-12-16
US11059789B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
MX2021002380A (es) Conjugados de isoquinolina-esteroide y usos de los mismos.
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MY197845A (en) Pharmaceutical composition
EP4445954A3 (en) Cellular models of and therapies for ocular diseases
MX2020010369A (es) Particulas implantables y metodos relacionados.
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX2014012945A (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
WO2014143754A3 (en) Prostamide-containing intraocular implant
WO2016060564A8 (en) Body sculpting
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
EP4596543A3 (en) Farnesoid x receptor agonists and uses thereof
EP4410312A3 (en) Topical cyclosporine-containing formulations and uses thereof
WO2019241672A3 (en) Glycosylated comp pilin variants, methods of making and uses thereof
NZ746468A (en) Methods of treating ocular conditions
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
MX393352B (es) Composicion para productos oftalmologicos